Join Altmore Capital for an exclusive WEBINAR on April 25th at 2:00 PM ET

Rescheduling Cannabis: Navigating the Implications of Its Potential Reclassification to Schedule III

At some point in the first half of 2024, there’s a strong chance that cannabis will be reclassified as a Schedule III controlled substance from a Schedule I controlled substance, as defined by the Controlled Substances Act.

The ripple effects of such a decision at the federal level could be enormous. 

And extensive.

To address the possibilities—and offset speculation from all sides of the issue, Altmore’s white paper, The Rescheduling Shuffle, addresses:

• What’s driving this reclassification initiative 
• How the shift to Schedule III could play out
• Potential pros and cons of the possible rescheduling
• The path forward for federal enforcement efforts
• Altmore’s thinking around the potential ripple effects

Read Altmore Capital’s White Paper HERE.

For more information please contact Spotlight Family Office Group at Info@SpotlightFamilyOffice.com.